<DOC>
	<DOCNO>NCT01627327</DOCNO>
	<brief_summary>The purpose study evaluate 24-hour spirometry effect ( FEV1 ) Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg daily compare tiotropium bromide inhalation powder 18mcg daily 12-week treatment period subject COPD risk co-morbid cardiovascular disease</brief_summary>
	<brief_title>Study Evaluate 24-Hour Pulmonary Function Profile Fluticasone Furoate/Vilanterol ( FF/VI ) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily Subjects With COPD Who Have Are At Risk Co-morbid Cardiovascular Disease</brief_title>
	<detailed_description>This randomize , double-blind , double-dummy , multi-center , parallel-group study . Subjects meet eligibility criterion Screening end 2-week Run-In Period enter 12-week Treatment Period . There 7-day Follow-up Period Treatment Period .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>Signed date write informed consent Male females ≥ 40 year age Females must postmenopausal use highly effective method avoidance pregnancy Established clinical history COPD ATS/ERS definition Postalbuterol spirometry criterion : FEV1/FVC ratio ≤ 0.70 FEV1 ≥30 ≤ 70 % predict normal ( NHANES III ) Former current smoker ≥10 pack year A history diagnose cardiovascular disease prior cardiovascular event include follow : Established ( i.e. , clinical sign image study ) coronary artery disease ( CAD ) Established ( i.e. , clinical sign image study ) peripheral vascular ( i.e. , arterial ) disease ( PVD ) Previous stroke Objectively confirm transient ischemic attack ( TIA ) ( i.e. , transient neurological deficit document healthcare professional ) Previous myocardial infarction ( MI ) ( Note : An MI within 6 month prior Visit 1 exclusionary ) OR Presence one follow cardiovascular risk factor ( addition former/current smoker ) : Current diagnosis hypertension Current diagnosis hypercholesterolemia Diabetes mellitus treat pharmacotherapy Current diagnosis asthma Subjects respiratory disorder include α1antitrypsin deficiency underlie cause COPD , active tuberculosis , lung cancer , bronchiectasis ( Note : focal bronchiectasis exclusionary ) , sarcoidosis , pulmonary fibrosis ( Note : focal fibrotic pulmonary lesion exclusionary ) , pulmonary hypertension , interstitial lung disease active pulmonary disease Lung volume reduction surgery within previous 12 month Clinically significant abnormality due COPD chest Xray CT scan Hospitalized poorly control COPD within 12 week Screening Poorly control COPD 6 week prior Screening , define acute worsen COPD manage subject corticosteroid antibiotic require treatment prescribed physician Lower respiratory infection require antibiotic 6 week prior Screening A moderate severe COPD exacerbation and/or lower respiratory tract infection ( include pnuemonia ) RunIn Period An abnormal , clinically significant find liver chemistry , biochemical , haematology test Screening ( Visit 1 ) upon repeat prior randomization An abnormal , clinically significant ECG find Screening ( Visit 1 ) upon repeat prior randomization An abnormal , clinically significant Holter find Screening ( Visit 1 ) upon repeat prior randomization ( subset subject ) Historical current evidence clinically significant ( opinion Investigator ) unstable disease cardiovascular ( e.g. , patient require ICD , pacemaker require ventricular pace rate set &gt; 60 bpm , uncontrolled hypertension , New York Heart Association Class IV ( New York Heart Association,1994 ) , know leave ventricular ejection fraction &lt; 30 % ) , neurological , psychiatric , renal , hepatic , immunological , endocrine ( include uncontrolled diabetes thyroid disease ) , peptic ulcer disease , haematological abnormality Carcinoma complete remission least 5 year History allergy hypersensitivity study medication ( e.g. , anticholinergic/muscarinic receptor antagonist , beta2agonist , corticosteroid ) component inhalation powder ( e.g. , lactose , magnesium stearate ) medical condition narrowangle glaucoma , prostatic hypertrophy bladder neck obstruction , opinion study physician contraindicates study participation use inhale anticholinergic . In addition , subject history severe milk protein allergy , opinion Investigator , contraindicate subject 's participation also exclude Known/suspected history alcohol drug abuse last 2 year Women pregnant lactate plan become pregnant Subjects medically unable withhold albuterol /salbutamol 4 hour prior spirometry test study visit Use certain medication bronchodilator corticosteroid protocolspecific time prior Visit 1 ( Investigator discuss specific medication ) Long Term Oxygen Therapy ( LTOT ) nocturnal oxygen therapy &gt; 12 hour day Participation acute phase pulmonary rehabilitation program within 4 week prior Screening study Failure demonstrate adequate compliance define completion Diary Card ( complete diary entry least 4 last 7 consecutive day ) , ability withhold COPD medication keep clinic visit appointment Noncompliance inability comply study procedure schedule visit History psychiatric disease , intellectual deficiency , poor motivation condition limit validity inform consent participate study Affiliation investigator site Women pregnant lactate plan become pregnant study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cardiovascular event</keyword>
	<keyword>Cardiovascular disease</keyword>
</DOC>